MANE
Veradermics, IncorporatedHealthcare · $4.9B market cap
Verdict
We can't put a fair value on MANE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow MANE
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold MANE. In Q2 2026, 1 opened a position. Who we track
Viking Global Investors
Viking Global Investors · as of Q2 2026
$192.0M
1,561,494 shares
Lee Ainslie
Maverick Capital · as of Q2 2026
$97.1M
789,980 shares
Moves in Q2 2026
New position: Lee Ainslie
About Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works